3-AMINOETHYL-N-AMIDINO-2,5-DIHYDROPYRROLE DERIVATIVES HAVING ARGININE MIMETIC PROPERTIES

Abstract: The present invention ocncerns new amidinopyrroline derivatives of formula (I) with the meanings of the symbols as given in the description as well as a process for their production and their use in pharmaceutical preparations.

Description: 3-AMIN0ETHYL-N-AMIDIN0-2.5-DIHYDR0PYR 0LE DERIVATIVES HAVING ARGININE MIMETIC PROPERTIES The present invention concerns new amidinopyrroline derivatives, processes for their production and their use thereof in pharmaceutical preparations It was found that compounds of the general formula (I) have the propeπies of an arginine mimetic Arginine mimetics are pharmacophores which can replace arginme or an argmyl residue for example in inhibitors Derivatives of (I) can replace arginine or already known arginine mimetics in biologically active substances and especially in therapeutically active substances In particular they can be used in inhibitors for serine proteases such as thrombin or trypsin inhibitors Inhibitors of thrombin inhibit the thrombin induced coagulation of fibrinogen in blood as well as the thrombin induced aggregation of blood platelets Thus they prevent the formation of coagulation thrombi and platelet-rich thrombi and can be used to treat and prevent diseases such as thromboses, apoplexy, cardiac infarction, inflammations and arteriosclerosis Thrombin the last enzyme of the coagulation cascade cleaves fibrinogen to fibrin which is cross-linked by factor XIII and becomes an insoluble gel which forms the matrix for a thrombus Thrombin activates platelet aggregation by proteolysis of its receptor on the blood platelets and in this manner also contributes to thrombus formation When blood vessels are damaged these processes are necessary to stop bleeding Under normal circumstances no measurable thrombin concentrations in blood plasma are present An increase of the thrombin concentration can lead to the formation of thrombi and thus to thromboembolic diseases which occur very frequently above all in industrial countries Thrombin is kept ready in the plasma in the form of prothrombin and is released from this by factor Xa Thrombin activates factors V, VIII and XI which then convert factor X into Xa By this means thrombin catalyses its own release which is why very rapid increases in thrombin concentrations can occur Thrombin inhibitors and factor Xa inhibitors can therefore inhibit the release of thrombin, and the platelet induced and plasmatic blood coagulation Trypsin is a digestive enzyme which is excreted by the pancreas when required When the pancreas is damaged oi inflamed the trypsin release which this causes can lead to tissue destruction Trypsin inhibitors can reduce this threat and be used for instance to treat pancreatitis In addition such arginine mimetics can be incorporated into active substances which are able to inhibit the binding of iigands that bind to their receptor via sequences containing RGD R.GD stands for the tπpeptide Arg-Gly-Asp Such ligands are for example fibrinogen, vitronectin or fibronectin Such active substances can be used to treat diseases which are due to thrombo-embolic events such as stroke, myocardial infarction or arterial occlusive diseases as well as inflammations, osteoporosis or tumour diseases The invention concerns compounds which contain the structural element I as a pharmacophore as well as modifications known to a person skilled in the art which can be derived from the parent substance of structure I, in which R l , R2 and Y can be the same or different and denote hydrogen or an organic residue Preferred organic residues are such which result in a biological active compound of general formula I Biological active means inter alia substances for plant protection and preferred pharmacological active compounds Prodrugs of such biological active compounds are also included in the preferred structures of formula I Prodrugs are substances which will be metabolized in vivo into the biological active compound An example, but not a limitation for prodrugs are esters which will be converted to free acids by the organism e g by the liver metabolism Especially preferred are such deπvates of compounds of the general formula I wherein an arginine substructure or a known arginine mimetic substructure in a biological active sustance is substituted by the backbone structure of formula I or I" wherein the jagged bonds represent in said bioiogical active compound the positions of the optional chemical bonds of the arginine or known arginine mimetic substructure which is substituted by the arginine mimetic structure (V) or (I") of the invention A collection of pharmacological active compounds can be found in data bases for INNs (International Nonproprietary Names) which are hereby incorporated by reference In particular compounds of the general formula (I) are preferred in which R I , R2 denote hydrogen, an ammo acid, peptidyl, alkylsulfonyl or arylsulfonyl residue, Y denotes hydrogen or a residue of the formula COX, X denotes hydrogen or an OR3 or NR1'R2' residue, R3 denotes hydrogen or lower alkyl such as methyl, ethyl, propyl or butyl preferably ethyl and Rl', R2' can be the same or different and have the meanings of the residues Rl and R2 Amino acid residue usually denotes the residue of a natural or unnatural amino acid Unnatural amino acids are understood as α-, β-, γ- and ω-aminocarboxylic acids as well as derivatives thereof Derivatives are in particular understood as compounds which are alkylated on the amino group or the carboxy group Derivatives are also included which are either decarboxylated or deaminated Examples of such amino acids and derivatives thereof are stated in the examples and preferred compounds In particular these are D-amino acids, citrulline, homocysteine, homoserine, hydroxyproline, hydroxylysine, ornithine, sarcosine, tranexamic acid , Adc [3-(2-amιnoethyl)-2,5 dihydropyrrol-l -yl]-carbamidine], Ada [( l -amidino-2,5- dihydro- l H-pyrrol-3-yl)-aianιne], Cha [cyclohexyl-alanine], Choi [2-carboxy-6- hydroxy-octahydroindol], norLeu(cyclo)-Gly [3-amιno-2-oxo-hexahydro- 1 -azepine- acetic acid], Pcs [4-pιperidιne carboxylic acid], Pip [pipecolic acid], Pla [phenyllactic acid], N- e-Phe, HOOCCH2-Phe, HOOCCH2-Cha, 1 -carboxy-perhydroιso- quinoline, N-cyclopentylglycine, EtSO2-Phe, N-(BuSO2-NorLeu(cyclo)-Gly A peptidyl residue is understood as a residue composed of any desired number of natural or unnatural identical of different amino acids Peptidyl residues with 1 -50 amino acids are preferred and those with I , 2, 3 or 4 amino acids are particularly preferred Alkyl usually denotes a linear or branched alkyl residue with one to six carbon atoms Aryl usually denotes a carbocycle with 6 to 14 C atoms or a 5- or 6-membered heterocycle with 1 , 2 or 3 heteroatoms selected from O, N or S Unsubstituted or optionally substituted phenyl or naphthyl residues are preferred The arginine mimetic (I) in which Rl and R2 denote hydrogen is produced by well- known methods Production from the precursor (II) is advantageous. in which the primary ammo group is protected preferably by reaction with phthalic acid anhydride to form the phthalimide, then the secondary amino group is amidated preferably by the methods described in Bannard et al , Can J Chem 1958, I 54 I and subsequently the phthalimido group is cleaved preferably by hydrazine hydrate and subsequent treatment with hydrochloric acid Compounds of the formula (II) in which Y denotes hydrogen can be produced by a) reducing the amide group of a compound of formula (III), preferably with lithium aluminium hydride or lithium borohydπde in the presence of tπmethylchlorosilane or b) by rearranging the exocyclic double bond of a compound of the general formula (IV) in which R5 denotes a protecting group for example a benzoyl group, an alkvloxycarbonyl group or a benzyloxy-carbonyl group into the isomei with an endocyclic doubie bond and subsequently cleaving the protecting groups The rearrangement of the exocyclic double bond to the endocyclic double bond is carried out in the presence of lyes preferably sodium hydroxide solution as described analogously in M I Labouta et al , Acta Chem Scand Ser B 1982, 669 - 674 This is followed by the cleavage of the protecting groups R5 and of the phthalimido group c) to use the process as shown in scheme 1 SCHEME 1 (6) (5) (4) To Scheme 1 a) NaBH,CN/MeOH/RT, b) PhCOCI/Py/DMAP/RT, c) DBU/toluene/RT/16h, d) D1BAL-H/THF/-78 °C, e) Ac 2 O/Py DMAP/0 °C, 0 Dι-methyl-malonate/Pd(PPh 3 ) 4 /THF/20h reflux, g) DMF NaCl/H 2 O/150 °C/30 mm h) LiOH/MeOH/H 2 O/l N HCl i) Diphenyl-phosphoryl-azide/THF/NEt 3 /80 °C, 12 h, Cl 3 CCH 2 OH/THF/CuCl/2h reflux j) 4 N HC1/16 h, (23) (scheme 2) EtN(i-Pr) 2 k) Zn/AcOH/RT 1) 4 N HCl in dioxane Compounds of the general formula (II) in which Y denotes a carboxyl group can be produced according to the process outlined in schemes 2 or 3 VIII) T he compound (III) is produced from compounds of the general formula (XIV) wherem R5 has the above-mentioned meanings with a reagent that activates the carboxyl group for example thionyl chloride or chloroformic acid isobutyl ester followed by ammonia Subsequently the protecting group R5 is cleaved preferably with hydrochloric acid in dioxane or with trifluoroacetic acid oi with hydroden bromide in glacial acetic acid Compounds of the general formula (XIV) are known for example from M I Labouta et al , Acta Chem Scand Ser B, 1982, 669 - 674 or can be produced by the processes described in this publication The compounds of the general formula (IV) are produced by reacting compounds of the general formula ( XV) with the compound (XVI) according to a Wittig reaction wherein R denotes for a protecting group This Wittig reaction and the reagent (XVI ) are described in Ch Sellier et al , Liebigs Ann Chem 1 92, 3 1 7 - 324 The compounds (XV) are descπbed in A G Schultz, Tetrahedron 1980, 1 757 - 1761 Comments on scheme 2 — R3 and R have the above-mentioned meanings, --R6 denotes an alkyl or aryl residue such as a methyl, ethyl, tπfluoromethyl, phenyl, tosyl or 4-nιtro-phenyl residue, preferably a methyl or tosyi residue — L usually denotes a sulfonic acid residue such as a methanesulfonic acid, tπfluoromethanesulfonic acid or p-toluenesulfinic acid residue, or a halogen such as chlorine, bromine, iodine or actate, — MHal denotes a metal halogenide such as NaCl, NaBr, KI, MgC12 or MgBr2, - compounds of formula ( V ) are descπbed in Timothy L et al , J Org hem 48 1 1 29- 1 1 3 1 ( 1983), -- Conversion of an alcohol of formula (V) into a sulfonic or acetic acid ester of formula (VI) is achieved by standard methods of organic chemistry — The conversion of an alcohol of formula (V) into a halogenide of formula ( V I ) by means of N-chloro-succinimide, N-bromosuccinimide or N-iodosuccinimide ( NCS, NBS, N I S) in the presence of triphenylphosphine (Ph3P) is carried out analogously to corresponding literature methods (e g Rozwadowska D , Tetrahedron Asv , 4, 1619- 1624 ( 1993 )), — A compound of formula (X) is converted into a compound of formula ( I I) by means of Claisen rearrangement analogously to methods which are described in Kazmaier U et ai , Tetrahedron 52, 94 1 -954 ( 1996), -- The epoxide opening of an epoxide of formula (XII) to form an allvl alcohol of formula ( XI ) is carried out under conditions which are described in Joshi V S et al Tetrahedron, 24, 587-5830 ( 1 68), — Compounds of formula ( XI II) are described in Grubbs H et al , J Am Chem Soc . I 14, 7324-7325 ( 1992), — The decarboxylation of malonic esters by means of metal halogenides in dimethylsuifoxide and at a high temperature is described in Krapcho \ P et al T etrahedron Lett 957 ( 1973) oc- .H (6) N N ' (18) " I o Scheme 3 a) 4 N HCl/ 1 6 h, (23)/EtN(ι-Pr) 2 b) (24 )/H DS/n-BuLι/- 78 °C d) Boc,O/EtN(ι-Pr) 2 /acetonιtπle/ 16 h e) LιOH/Tl lF- eOH-H 2 O 0 4 N HCl in dioxane g) CI ,CCH ? OCOCl/DMAP/Py/RT/12 h h) Zn/AcOH/RT Some of the compounds of the general formula (i ) have one oi sevei dl asymmetric centres Hence optically activ e forms are also a subject matter of the invention as well as tautomers The invention also concerns all salts of compounds of the general formula ( I) Salts are primarily the acid addition salts Physiologically acceptable salts come mainly into consideration for pharmaceutical purposes Examples of salts of the compound of formula ( I ) which can be used physiologically are salts with physiologically tolerated mineral acids such as hydrochloric acid, sulfuπc acid, sulfurous acid or phosphoric acid or with organic acids such as methane-sulfonic acid, p-toluenesuifonic acid, acetic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaπc acid, succinic acid or salicylic acid For the production of pharmaceutical agents the substances of the general formula ( I ) and their salts are admixed with suitable pharmaceutical carrier substances, aromatics, flavourings and dyes and are for example formed as tablets or dragees or are suspended or dissolved in water or oil for example in olive oil with addition of appropriate auxiliary substances The substances of the general formula ( I ) and their salts can be administered enterallv or parenterally in a liquid or solid form Water is preferably used as the injection medium which contains the usual additives in injection solutions such as stabilizing agents, solubilizers or buffers Such additives are for example tartrate and citrate buffer, complexing agents (such as ethylenediamine tetraacetic acid and non-toxic salts thereof) and high molecular polymers such as liquid polyethylene oxide to reguiate viscosity Solid earners are e g starch, lactose mannitol, methylcellulose talcum, highly-dispersed silicic acids, high molecular fatty acids (such as stearic acid) animal and vegetable fats and solid high molecular polymers (such as polyethylene glycols) Preparations which are suitable for oral administration can optionally contain flavourings and sweeteners The compounds are usually administered in amounts of 10- 1 500 mg per day with regard to 75 kg body weight It is preferred to administer 1 -2 tablets with a content of active substance of 5-500 mg 2-3 times per day The tablets can also be retarded in which case only 1 -2 tablets with 20-700 mg active substance have to be administered once per day The active substance can also be applied by injection 1 -8 times per day or bv continuous infusion in which case 50-2000 mg per day are usually adequate Description of the figures Fig I Spatial structui e of Λdc from D-Pla-D-Phe-1 -Choi- dc (thick l ods) in the enzyme trypsin (thin rods) from the X-ray structure of example 2 1 he spatial structure of the inhibitor DFPR in human thrombin is superimposed over this (inhibitor thin rods with spheres, thrombin thin lines) The sphere represents a water molecule The following abbrev iations are used in the examples Ac =- acetyl Ada - ( 1 -amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-alanιne Adc - [3-(2-amιnoethyl)-2,5-dιhydropyrrol- l -yl]-carbamιdιne Asp - aspartic acid Bn = benzyl Boc = tert butyloxvcarbonyl Bu - butyl Cbz = benzyloxycarbonvl Cha - cyclohexylalanme Choi = 2-carboxy-6-hydroxy-octahydromdole DBU = l ,8-dιazabιcyclo[5 4 0]undec-7-ene DIBAL-H = di-isobyle aluminum hydride DMAP - 4-Dιmethylamιnopvπdιne DMJ- = dimethylformamide eq = equivalent Et ~ - ethyl Fmoc = 9-Fluorenylmethoxycarbonyl Gly = glycme HMDS = hexamethyldisilazane i-Pr - iso-propyl Me = methyl NMM = N-methylmorpholine norLeu(cyclo)-Gly ■ 3-amιno-2-oxo-hexahydro- l -azepιne-acetιc acid Pcs = 4-pιperιdιne carboxylic acid Ph - phenyl Phe phenylalanine Pip pipecolic acid Pla - phenyllactic acid Pmc 2,2,5,7,8-pentamethylchroman-6-sulfonyl Pro = proline Py = pyridine Ser - serine t-Bu — tert -Butyl TB ' I V = 2-( I H-benzotrιazol- l -vl )- l ! 3 3-tetramthyluronιum letra.luorborate TCT - " I πtylchloπde-polvstvrene IΗF ~ tetrahydrofuran Troc = 2 2 2-Trichloπne-ethoxycarbonyl Tyr - tyrosine Trp ^ tryptophane X = retention time Val - valine The (\ N,O-backbone of Ada and Adc are the backbone siiuctures w hich substitute the arginine or arginine mimetica structure in biological active substances of the invention, wherein OH-function of the carboxylic acid group of Ada may be replaced by another backbone atom, e C, N or S Apart from the compounds mentioned in the examples and compounds derived by combining all meanings of the substituents stated in the claims the following are preferred within the sense of the present invention 1 N-Me-D-Phe-Cha-Adc 2 HOOCCH2-D-Phe-Pro-Adc 3 HOOCCH2-D-Cha-Pιp-Adc 4 1 -Carboxy-perhydroisoquinolinyl-Pro-Adc 5 I -Carboxy-perhydroisoquinolinyl-N-cyclopentyl-Gly- Adc h EtS02-D-Phe-Pro-Adc 7 EtSO2-D-Phe-N-cydopentyl-Gly-Adc 8 N-(BnSO2-norLeu(cyclo)-Gly-Adc 9 3-( { 3-[2-( I -Amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-ethyl]-2,4-dιoxo- 1 ,2,3,4- tetrahydro-quιnazolιn-6-carbonyl }-amιno)-propιonιc acid 10 (4- j -[2-( I -amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-ethyl]-2-oxo-o\azolιdιn- ylmethoxy}-phenyl)-acetιc acid 11 -({ l-[2-(l-Amιdιno-2,5-dιhydro-lH-pyrrol-3-yl)-ethylcarbamoyl]-pιpeπdιn- carbonyl }-amιno)-3-pyπdιn-2-yl-propιonιc acid 12 (4-{ [2-( 1 -Amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-ethylamιno]-acetyl }-3- methoxycarbonylmethyl-ptperazιn-l-yl)-acetιc acid 13 [4-( { [2-( I -Amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-ethyl]-methylamιno }-acetyl)- phenoxy]-acetιc acid 1 [ 7-[2-( I -Amιdιno-25-dιhydro- 1 H-pyrrol-3-y|)-ethylcarbamoyl]-3-oxo-4- phenethyl-23,4,5-tetrahydro-lH-benzo[e][l,4]dιazepιn-2-yl}-acetιc acid 15 3 -(4-j >-[2-( l-Amιdιno-2 ^-dιhydro-1 H-pyrrol-Vy|)-ethyl]-2-oxo-ιmιda7θlιdιn- 1 yl}-phenyl)-propιonιc acid 16 4-{3-[2-( l-Amιdιno-25-dιhydro-IH-pyrrol-3-yl)-ethyl]-2-oxo-ιmιdazolιdιn- 1 -yl cyclohexane carboxylic acid 17 [5-(4-{ [2-( 1 -Amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-ethylamιno]-methyl } - pheno\ymethyl)-2-oxo-pyrrolιdιn-3-yl]-acetιc acid 18 [5-( j 4-[2-( I -Amιdιno-2,5-dιh dro- 1 H-pyrrol-3-yl)-ethylamιno]-pιperιdιn- 1 -yl j - acetyl)-2-carboxymethoxy-phenoxy]-acetιc acid 19 (4-{[2-(l-Amιdιno-2,5-dιhydro-lH-pyrrol-3-yl)-ethyl]-methyl-amιno}- [ 1 ,4']bιpιpeπdιnyl- 1 '-yl)-acetιc acid 20 3-{3-[2-(l-Amιdιno-2,5-dιhydro-lH-pyrrol-3-yl)-ethylcarbamoyl]- propionylaminoj-butvnc acid 21 3-13-[2-( I - Amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-ethylcarbamoyl]- propιonvlamιno}-3-phenyl-propιonιc acid 22 3-{ 3-[2-( l-Amιdino-2,5-dihydro-lH-pyrrol-3-yl)-ethylcarbamoyl]- propιonylamιno}-3-pyridιn-2-yl-propιonιc acid 23 3-{3-[2-( l-Amιdιno-2,5-dιhydro-lH-pyrrol-3-yl)-ethylcarbamoyl]- propιonylamιno|-pent-4-ynone carboxylic acid 24 3-(2-{3-[2-( l-Amιdιno-2.5-dιhydro-lH-pyrrol-3-yl)-ethyl]-ureιdo}-acetylamιno)- N-(carbo\y-phenyl-methyl)-succιnιc acid 25 3-(2- J 3-[2-( 1 -Amιdιno-2,5-dιhydro- 1 H-pyrrol-3-yl)-ethyl]-2-oxo-tetrahydro- pyπmidin- 1 -yl } -acetylamιno)-propιonic acid 26 { 4-[2-( 1 -Amidιno-2,5-dihydro- 1 H-pyrrol-3-yl)-ethylamιno]-cyclohexyl } -acetic acid 27 3-( Butane- 1 -sulfonvl)-2-(4- J [2-( I -amιdιno-2.5-dihydι - 1 H-pyrrol-3-yl)- ethylamιno]-methyl }-benzyl)-propιonιc acid 28 2-{2-[2-Amιno-3-( l-amιdιno-2,5-dιhydro-l H-pyrrol-3-yl)-propιonylamιno]- acetylammo ] -succinic acid 29 I -{ 3-[2-( 1 -Amιdmo-2,5-dihydro- 1 H-pyrrol-3-yl)-ethyl]-2-oxo-oxazolιdιn-5- ylmethyl j -piperidin-4-carboxylιc acid 30 Ada-Gly-Asp-Ser 31 Ada-Gly-Asp-Ser-NH2 32 Ada-Gly-Asp-Phe 33 Ada-Gly-Asp-Phe-NH2 s4 Λda-Glv-Asp- I\ι 35 Ada-Glv-Asp- " ivr-NH2 36 Ada-Gly-Asp-Trp 37 Ada-Gly-Asp-Trp-NH2 38 Ada-Gly-Asp-Val 39 Ada-Gly-Asp-Val-NH2 40 Pla-Phe-Choi-Adc Example 1 : D-Pla-D-Phe-L-Choι-Adc Production of the biomass Three 20 I glass cylinders with a pH regulator were filled with sterile filtered nutrient medium, each was inoculated with 50 ml preculture of Oscillatoπa agardhn from the collection of algae cultures of the Institute of Plant Physiology of the University of Gottingen ( strain number B3 82) and incubated for ca 14 days at a constant pH of 8 a temperature of 20°C and an average irradiation of " 50 Wm-2 under continuous gassing with sterile-filtered room air Nutrient medium 3 6 mg CaCI2 x 2 H2O, 20 3 mg Ca(NO3 )2 x 4 H2O 2 7 mg KCI 1 5 mg K2HPO4 76 0 mg MgSO4 x 7 H2O, 84 0 mg NaHCO3, 1 ml trace element solution, 1000 ml deionized water Trace element solution 875 mg Na4EDTA, 9 7 mg Co(NO3)2 x 6 H2O 284 mg FeC12 x 6 H2O, 72 2 mg MnC12 x 4 H2O, 25 2 mg Na2MoO4 x 2 H2O, 43 7 mg ZnSO4 x 7 H2O 1000 ml deionized water (K Zielinski, Dissertation Univ Freiburg 1988, p 23 ) Processing of the 3x20 1 cultures At the time of harvesting the three 20 I cultures were combined and the cells and nutrient solution were separated by gentle centrifugation (5000 g, 10 min) The biomass was frozen at -20°C and subsequently lyophilized The lyophilisate (ca 30 g) was extracted once with 1000 ml and twice with 500 ml methanol and the combined methanol phases were evaporated to dryness The methanol extract (ca 7 g) was taken up in 500 ml water and shaken out three times with 500 ml butanol each time The butanol phases were combined and concentrated to dryness at 40°C on a rotary evaporator The butanol extracts were combined (ca 5 g), taken up in 150 ml methanol and absorbed onto ca 25 g LiChroprep-CN phase (25-40 μm) and chromatographed over a LiChroprep-CN column (column 52 x 356 mm; mobile phase gradient water/acetonitrile/trifluoroacetic acid from ( 100 0 0 1 ) to (50 50 0 1 ), total elution volume 5 I) The fractions containing D-Pla-D-Phe-L-Choi-Adc which were identified with the aid of TLC or the thrombin time prolongation assay were pooled and evaporated to dryness at 40°C on a rotary evaporator. The concentrate (ca I g) was dissolved in 100 ml methanol, absorbed to ca 5 g silica gel LiChroprep Si60 ( 1 5-25 μm) and chromatographed over a silica gel column (26 \ 360 mm) with 1 500 ml chloroform/methanol/glacial acetic acid/water (65 25 3 4) as the mobile solvent The pooled and concentrated fractions containing D-Pla-D-Phe-L-Choi-Adc (ca 200 mg) were taken up in 3 ml methanol for the further purification and further separated by high pressure liquid chromatography on Nucleosil- 100 RPI 8 ( 10 μm, column 20 x 250 mm) with water/acetonitrile/trifluoroacetic acid (70 30 0 1 ) as the mobile solvent The concentrated fraction containing D-Pla-D-Phe-L-Choi-Adc (20 mg) was taken up in I ml methanol and subjected to a further high pressure liquid chromatography (column Nucleosil- 100 R 18, 10 μm, 20 x 250 mm, mobile solvent 50 mM phosphate buffer pH 7 8/ acetonitrile (70 30)) A fraction was obtained which only contained D-Pla-D-Phe-L-Choi-Adc. This was concentrated to ca 5 ml aqueous solution In order to remove the buffer the aqueous concentrate was applied to a Nucleosil- 100 RP 18 column ( 15 x 100 mm), whereby D-Pla-D-Phe-L-Choi-Adc was bound to the stationary phase After washing with 100 ml water, the D-Pla-D-Phe-L-Choi-Adc was eluted with 200 ml water/methano! (1090) The methanolic eluate was evaporated to dryness at 40°C on a rotary evaporator ca 3 mg pure D-Pla-D-Phe-L-Choi-Adc was obtained as a colourless phosphate salt Analytical data for D-Pla-D-Phe-L-Choi-Adc: a) Mass spectrometry The LSIMS spectrum of D-Pla-D-Phe-L-Choi-Adc yielded a pseudomolecule ion at MH+ 617 Da High resolution measurements in the positive LSIMS mode resulted in MH t 617345 Da which enabled C34H44N6O5 to be derived as the elemental composition of the neutral compound The MS/MS spectrum of the molecular ion MH+ produced a series of daughter ions which confirmed the chemical structure derived for D-Pla-D-Phe-L-Choi-Adc Experimental conditions The compound was measured at a resolution of ca 5000 in the LSIMS mode against PEG as the reference substance in the peak match mode Experimental data LSIMS selected peaks (M/Z rel int ) 13692, 154100, 1769, 1 36,2396,28914,30719.3313,35834,3812,3996. 4692.5253, 5937, 61786,6478.6673.7136 MS/MS of MH+ selected peaks (M/Z rel int ) 9410, 12064, 140.39, 1533, 1819.20916, 2502, 2687.305 1.32013, 149 I, 3773,4532,46916, 5403, 5655 Assignment of the fragments (daughter ions) 268 120 140 (b) Gas chromatographic analysis of the acid total hydrolysate of D-Pla-D-Phe-L- The molecular components D-Pla and D-Phe could be detected in the acid total hydrolysate of D-Pla-D-Phe-L-Choi-Adc by gas chromatographic analysis on a chiral phase Furthermore a peak was identified in the gas chromatogram by means of GC- MS coupling which could be assigned in the El mass spectrum to the molecular component Choi on the basis of the two typical masses of 419 Da (the moleculai ion (M + ) of N,O-dι-tπfluoroacelyl-Choι-n-prop>l estei ) and 332 Da (the fragment [M- C (O)OC3H ] + ) Experimental conditions The sample was hydrolyzed for 24 h with 6 N hydrochloπc acid and denvatized after blowing off the hydrochloric acid 0 5 ml 4 N hydrochloric acid in n-propanol was added to the dry hydrolysate for the detection of D-Phe and Choi and the reaction mixture was heated for 30 minutes to 1 10°C The excess reagent was completely blown off The subsequent acylation was carried out for 10 minutes at 150°C with trifluoroacetic acid anhydride The reagent was again completely blown off and the sample was taken up in solvent For the detection of D-Pla 0 5 ml 4 N hydrochloπc acid in methanol was added to the dry hydrolysate and the reaction mixture was heated for 10 minutes to 1 10°C The excess reagent was completely blown off The subsequent aminoiysis was carried out at room temperature with n-propy!amιne Afterwards it was silylated for 20 minutes at 70°C with hexamethyldisiiazane The denvatized products of hydrolysis were analysed by capillary gas chromatography on a chiral phase A 20 m capillary with an inside diameter of 0 28 mm and a film thickness of 0 25 μm was used which is covered with Chirasil Val A flame-ionization detector was used for the detection The peaks were assigned in the case of D-Phe and D-Pla by comparing the retention with those of reference substances In the case of Choi a sector field mass spectrometer was used for the detection ( c) NMR spectroscopy The structure of the compound of example I was elucidated and confirmed by NMR spectroscopy (2D NMR, HMBC. HMQC, COSY (DQr-H H-COSY b COSY ) fOCSY, ROESY) Example 2: The compound of example 1 cocrystallizes with the bovine serine protease trypsin It was possible to derive the connectivity of the inhibitor in the complex with bovine trypsin from the high resolution crystal structure of the serine protease inhibitor D- Pla-D-Phe-L-Choi-Adc Comparison with an arginme-containing inhibitor showed that D-Pla-D-Phe-L-Choi-Adc contains an arginine mimetic The inhibitoi D-Pla-D-Phe-L-Choi-Adc resembles the known thrombin inhibitor ( D)- Phe-Pro-Arg (DFPR) along the main chain T ' here are differences at the N-terminus (an additional residue), at the proiine analogue (a condensed ring with a hydroxy group) and at the C-terminus (no carboxylate and a guamdino group partιall\ integrated into a five-membered ring) A comparison between the X-ray structure of D-Pla-D-Phe-L-Choi-Adc with trypsin and that of the trombin-DFPR complex (Bode, W , Mayr, I , Baumann, U , Huber, R , Stone, S , & Hofsteenge, J ( 1989) EMBO Journal 8, 3467-3475) clearly showed this similarity If both X-ray structures are superimposed, the DFPR inhibitor lies within the electron density of D-Pla-D-Phe-L-Choi-Adc Deviations only occur with respect to the differences in the side chain described above The f o-Fc electron densities phased independently of the stated inhibitoi sti ucture confirmed the chemical structure of the molecular building block Adc The five- membered ring is obvious The spatial geometry of the electron density corresponds to a double bond in an equivalent position to the C of arginine The planaπty of the density is also consistent with a nitrogen atom in the N equivalent position From this the guamdino group is deduced The refinement of the X-ray stiucture of the inhibitor D-Pla-D-Phe-L-Choi-Adc with the protein structure - at first with the appropriate geometric restraints, subsequently without any restraints - showed that the molecular building block Adc of D-Pla-D- Phe-L-Choi-Adc binds as an arginine analogue (Fig 1 ) The additional ring atoms replace a water molecule The other specific hydrogen bridges as well as the spatial position of the corresponding atoms remain almost identical Description of the methods of X-ray structural analysis Crystallization Bovine β-irypsin (SIGMA) was repunfied (D D Schroedei , E Shaw ( 1968) J Biol Chem 243, 2943-2949) and lyophilized For crystallization preparations 3 5 mg of the lyophilisate (70 % w/w beta trypsin, 20 % benzamidine, 10 % CaCI2) was dissolved in 30 μl distilled H2O and mixed 1 I with the precipitating solution ( 1 6 M ammonium sulfate, 100 mM ιmidazole H2SO4, pH 6, 0 02 % sodium azide) Crystals were produced by vapour diffusion (6 μl drops protein solution/4 ml precipitation solution) Benzamidine was replaced by D-Pla-D-Phe-L-Choi-Adc in the crystal by successive soaking I ) twice for 2 hours in a pure harvest solution (2 5 M ammonium sulfate, TRIS/HCI pH 8 10 mM CaCI2) in order to remove benzamidine and 2 ) overnight in inhibitor solution ( 1 76 mg D-Pla-D-Phe-L-Choi-Adc dissolved in 176 μl harvest solution) Data collection, evaluation The crystal was oriented with a 4-circle goniometer from Siemens The X-ray source was a copper rotating anode Rigaku Rotaflex-generator (45k V, 120 mA) equipped with a curved graphite monochromator The diffracted reflexes were measured with a Siemens XI 000 area counter A total of 2464 recordings (width 0 1 degree) of four orientations were made corresponding to a theoretical completeness of 99 % for a resolution of 1 6 A (estimated with the program ASTRO (Siemens Industrial Automation. Inc., Madison, WI , USA)) Automated indexing and data evaluation were carried out using SADI E and SAI NT (Siemens Industrial Automation. Ine . Madison. WI ) ( see Table I ) Fable I : Crystallographic data and refinement statistics Recording turning range. 0. 1 degree crystal detected removal 1 1 65 cm recording time'90 sec total number of recordings 54 1 +54 1 +54 1 +84 1 =2464 cell dimensions 63 3 1 A, 63 57A, 69 06A. 90 deg, 90 deg, 90 deg spatial group P2( 1 )2( 1 )2( 1 ) total reflexes 65572 independent reflexes. 40648 positive reflexes 34497 positive reflexes after 2 sigma selection. 28962 Total R-merge ( 5 - 1 .5 A) 4.2 % Completeness after resolution Model refinement (p=proteιn,s^solvent,ι=inhibitor, r=-πgιd body refinement, c=Powell conjugate gradients refinement, t=B-factor refinement, b=bonds. a-angles) Cvcle A I OMS(p,s,ι) % R-factor( r,c,t ) RMS from ιdealιtv(b,a) 1 1630,23,0 28 7,27 2,23 4 0 007, 1 97 2 1630,23,0 -, 22 8,22 5 0 006, 1 72 3 1630,23,34 -, 2 1 7,2 1 5 0 007, 1 74 4 1630,23,45 -. 2 1 5,2 1 4 0 006, 1 80 Electron density calculation, interpi etatiυn The first electron density was phased with the I 5 A resolved P2( 1 )2( 1 )2( I ) X-ray structure of trypsin (H D Baπunik, J Summers, H H Baπsch, J Mol Bio 2 10, 81 3, 1989) from the Brookhaven databank ( 1TLD, Abola, E E Bernstein, F C , Bryant, S H Koetzle, T F & Weng, J ( 1987) in Crystallographic databases - lnfoimation Content. Software Systems. Scientific Applications, Allen. F H , BerghofT & G , Sievers, R , eds , Data Commission of the International Commission of the International Union of Crystllography (Bonn/ Cambridge/Chester, 1987), 107- 132) after structural and B factor refinement using XPLOR (Molecular Simulations Incorporated MSI AG, Basel Switzerland) This density clearly showed the general orientation of the inhibitor Additional refinement cycles improved the densities and thus enabled the determination of the connectivities of the basic group in D-Pla-D- Phe-L-Choi-Adc It was also possible to likewise determine all other positions of the inhibitor except the first phenyl πng of osciilaπn which probably binds in a disordered manner Example 3: HOO HOOC-CH 2 -D-Cha-(N-cyclopentyl)-Gly-Adc (a) 4-Oxo-pyrrolidine-l ,3-dicarboxylic acid \-tert. butylester 3-ethylester (J Coopet et al J Chem Soc Perkin Trans 1 . 1993. 13 13- 13 1 8) To a refluxing suspension of 1 58 g (66 mmol) sodium hydride in 100 ml THF was added dropwise a solution of 1 2 79 g (60 mmol) N-/fr. -butvlo\ycarbonyl-glycιne ethyl ester and 7 1 5 g (66 mmol) ethyl acrylate in 100 ml THF After the addition was complete the mixture was heated to reflux for additional 2 h The clear solution was cooled lo room temperature, poured on 100 ml ether/ 100 ml water and acidified under vigorous stirring with I N hydrochloric acid against methyl orange The layers were separated and the aqueous layer was extracted three times with ether The combined oiganic layers were washed with sat sodium bicarbonate and brine, dried over MgSOj and evaporated Shoπ-path distillation of the residue gave 10 92 g ( 7 1 0 o) 4-oxo-pvrrolιdιne- 1 -lerl butylester 3-ethylester as a colorless oil, b p 1 19 - 1 22 °C (0 2 mbar), which solidified on prolonged standing in the freezer GC71MS ( HP 5890 l l/HP 5972, column HP 5, 30 m x 25 mm x 0 25 μm film thickness, carrier gas helium, temperature gradient 50 °C, 3 mm, then with 20 °C/mιn to 250 °C ) t R = 9 68 mm ml/ f° 'o] " 1 85 (2 ), 1 30 ( 1 0), 1 1 2 ( 1 8), 85 (6), 57 ( 100) b) 4-Hydroxy-pyrrolidine- l ,3-dicarboxylic acid l-tert.-butylester 3-ethylester I o a solution of 5 1 5 g (20 mmol) 4-oxo-pyrrolιdιne- 1 3-dιcarboxylιc acid I -tun butylester 3-ethylester in 30 ml methanol was added I 88 g (30 mmol ) sodium cyanoborohydπde and a small amount of methylorange With stirring the pH was adjusted to 3 by dropwise addition of 1 N hydrochloric acid (color change from yellow to orange) After no more acid was consumed the mixture was stirred for one hour The solvent was evaporated /// vacuo and the residue was partitioned between ethyl acetate and water I he organic layer was washed twice with watei then with brine. dried over magnesium sulfate and evaporated The residual yellow oil was used in the next step without any further purification GC/ S (HP 5890 II/HP 5972, column HP 5, 30 m x 25 mm x 0 25 μm film thickness carrier gas helium temperature gradient 50 °C 3 mm then with 20 °C mm io 250 °( ) tu - 12 44 min (no separation of diastereomers) m/z [%] = 259 (M ,0 3), 241 (0 7), 202 (5), 186 (7) 1 58 ( 10), 1 12 ( 14), 68 ( 3 1 ) 57 ( 100) c) 4-Benzoyloxy-pyrrolidine-l ,3-dicarboxylic acid l-tert.-butylester 3-ethylester To an ice-cooled solution of the crude 4-hydroxy-pyrrolιdιne- 1 3-dιcarboxyhc acid 1 - l n -butylester 3-ethylester from the reduction descπbed above and 244 mg ( 2 mmol ) DMAP in 40 ml pyπdine were added dropwise 3 51 g (25 mmol) benzoyl chloride After the addition was complete, the ice bath was removed and the mixture was stirred at room temperature for 2 h The mixture was diluted with ethyl acetate an poured on ice The organic layer was separated, washed with water sat CuSO 4 water and brine, dried over MgSOj and evaporated The lesidual yellow oil was used in the next step without further purification GC7MS ( HP 5890 II/HP 5972. column HP 5, 30 m x 25 mm x 0 25 μm film thickness, carrier gas helium, temperature gradient 50 °C, 3 mm, then with 20 °C/mιn to 250 °C) t κ = 17 28 and 17 38 min ( I I -mixture of cis/trans-isomers) m/z [%] = 318 (0 1 ), 290 (5), 262 (2), 241 (2), 185 (29), 141 ( 10), 1 12 (23), 105 ( 53 ), 77 (27) 68 ( 100), 7 (97) d) 2,5-Dihydro-pyrrole- l ,3-dicarboxylic acid I -tert. -butylester 3-eth I ester I o a solution of the crude 4-benzoyloxy-pyrrolιdιne- i , 3-dιcarbo\ylιc acid I -ten - butylester 3-ethylester from the benzoylation described above in 75 ml dry toluene was added 4 1 I g (27 mmol) DBU The dark, heterogeneous mixture was stirred at room temperature for 16 h After this time no starting material was delectable by FLC and GC analysis The mixture was filtered through a short column of silica (elution with petrolether/ethyl acetate 1 1 ) and evaporated Bulb-to-bulb distillation of the residual slightlv yellow oii gave 4 l o g (86 %) 2 5-dιhydro-pv rrole- 1 3-dιcarboxvlιc acid [ -ten -butylester 3-ethyl ester as a colorless oil b p 1 10 °C70 2 mbai which slowly solidified to a waxy mass on standing in the freezer GC/MS (HP 5890 II/HP 5972, column HP 5 30 m x 25 mm x 0 25 μm film thickness carrier gas helium temperature gradient 50 °C 3 mm then with 20 °C/mιn to 2^0 °C) t κ = I I 94 min mz[%] - 241 (M , I 4), 196(0.4), 185(11), 168(11), 140(14), 112 (17), 68 (24), 57 (100) 'H-NMR (CDC1., 300 MHz) δ = 127 (t, J = 71 Hz, 3H, OCH2CH3), 143, 1.44 [2s, 9H, C(CH 3 ) 3 ]", 425 (d, J = 71 Hz, 2H, OCH 2 CH,), 415 - 427 (br m, 4H, 2-H, 5-H), 666 - 671 (m, 1 H, 4-H) ppm "Double set of signals due to hindered rotation l3 C-NMR(CDCI-„ 75 MHz) δ - 1416, 1420 (q, -CH 2 -CH,)*, 2845 [q, -C(CH-,)-,], 5176, 5199, 53.62, 5384 (4t, C-2, C-5)*, 6069(1, -CH . -CH,), 7984 [s, -C(CH.).], 13229 (s, C-3).13644. 13655 (2d. C-4)*, 15386, 15408 (2s, -NCOO-)*, 16275 (s. COOEt) ppm e) 3-Mydroxymethyl-2,5-dihydro-pyrrole-l-carboxylic acid tert. -butylester To a solution of 543 g (225 mmol) 2.5-dihydro-pyrrole- 1 ,3-dicarboxy e acid I -ten. - butylester 3-ethyl ester in 50 ml THF, cooled to - 78 °C was dropwise added 50 ml of a IN D1B L-H solution in hexane. The mixture was allowed to warm to room temperature overnight As TLC analysis indicated complete consumption of starting material, the mixture was cooled in an ice bath and 1.90 g water were cautiously added, followed by 190 g 15 % aqueous NaOH and 5.70 g water. The white precipitate was filtered off, washed thoroughly with ether and the combined filtrates were evaporated Bulb-to-bulb distillation of the residual pale yellow oil gave 413 g (93 %) 3-hvdroxvmethyl-2,5-dihydro-pyrrole- 1 -carboxylic acid ten. -butylester as a colorless oil, b p 130 °C (02 mbar) GC/MS (HP 5890 IIHP 5972, column: HP 5, 30 m x 25 mm x 025 μm film thickness, carrier gas helium, temperature gradient 50 °C, 3 min, then with 20 °C/min to 250 °C) m/z[%] = 199 (M , I), 143(10), 142 (13), 126(13), I 12(12), 80(10), 68(45), 57 (100) 'H-NMR (CDCI-., 300 MHz) δ = 144 (s, 9H, -Bu), 409 (br. m, 4H, 2-H, 4-H), 418 (br. s, 2H, CH OH), 563 (br d, IH, 4-H)ppm 1J C-NMR (CDCI „ 75 MHz) δ - 28 5 [q, C(CH,h], 52 8, 53 0, 53 2, 53 3 (4t, C-2, C-5) ' , 57 7, 59 8 (2d, CH 2 OH)Fehler! Textmarke nicht definiert., 79 5 [s, C(CH 3 ) 3 ], 120 0, 120 3 (2d, C- 4)Fehler! Textmarke nicht definiert., 1 9 6 (s, C-3), 154 4 (s, COO/Bu) ppm Double set of signals due to hindered rotation f) 3-Acetoxymethyl-2,5-dihydro-pyrrole- 1 -carboxylic acid tβrt. -butylester To an ice-cooled solution of 4 13 g (20 7 mmol) 3-hydroxymethyl-2,5-dihydro- pyrrole- 1 -carboxylic acid ten. -butylester and 244 mg (2 mmol) DMAP in 50 ml pyridine was added 3 06 g (30 mmol) acetic anhydride The mixture was stirred for 30 mm at 0 °C, then for additional 60 mm at room temperature The mixture was poured on ice and extracted twice with ether. The combined organic layers were evaporated in vacuo, dissolved in ether, washed with sat CuSO , water and brine and dried over MgSO Evaporation and bulb-to-bulb distillation gave 4 82 g (97 %) 3-acetoxy- methyl-2,5-dihydro-pyrrole- 1 -carboxylic acid ten. -butylester as a colorless oil, b p 105 C C (0 2 mbar) GC MS (HP 5890 II/HP 5972, column HP 5, 30 m x 25 mm x 0 25 μm film thickness, carrier gas helium, temperature gradient 50 °C, 3 min; then with 20 °C/min to 250 °C) t R = I I 87 min m/z f%] - 241 (M . 0 2), 226 (0 1 ), 185 (5), 166 (5). 125 ( 18), 108 (3), 8 1 ( 1 3), 80 (23 ), 57 ( 100) 'H-NMR (CDCh, 300 MHz) δ = 1 43, 1 44 [2s, 9H, C(CH;) .]*, 2.04, 2.06 (2s, 3H, OOCCH ,)*, 4 05 - 4 12 (br m, 4H, 2-H, 5-H), 4 61 (br d, J = 5 7 Hz, 2H, CH 2 O), 5 66 - 5 73 (br m, I H, 4-H) ppm I C-NMR (CDC1,, 75 MHz) δ = 20 7 (q, OOCCHj), 28 4 [q, C(CH.),], 53 0. 53 2. 53 3 (3t, 2-C, 5-C)\ 60 8 (t, CH OAc), 79 5 [s, C(CH ,) J ], 123 4, 123 8 (2d, C-4)*, 134 5, 134,6 (2s, C-3), 154 1 (s, NCOO), 170 5 (s, OOCCH,) ppm g) 2-(l-tt'rt.-Butoxycarbon l-2,5-dihydro-lH-pyrrol-3-yl-methyl)-malonic acid dimetylester 528 g (40 mmol) dimethyl malonate were cautiously added to an ice-cooled suspension of 864 mg (36 mmol) sodium hydride in 80 ml THF The resulting clear solution was added to a solution of 482 g (20 mmol) 3-acetoxymethyl-2,5-dihydro- pyrrole- 1 -carboxylic acid ten -butylester and 462 mg (04 mmol) Pd(PPfh) in 40 ml I HI and the mixture was heated to reflux for 20 h The reaction mixture was cooled to room temperature, diluted with ether and quenched with sat NH_ιCl The organic layer was washed with sat NH 4 C1 and brine, dried over MgSO 4 and evaporated The residue was purified by flash chromatography (ethyl acetate/petrol ether 4 I to 21 ) and bulb-to-bulb distilled to yield 486 g (77 %) of 2-{\-tert -butoxycarbonyl-2,5- dihydro- 1 τ r -pyrrol-3-yl-methyl)-malonιc acid dimetylester as a colorless oil, b p 1 0 °C/02 mbar GC/MS (HP 5890 ll/HP 5972, column HP 5, 30 m x 25 mm x 025 μm film thickness, carrier gas helium, temperature gradient 50 °C, 3 min, then with 20 °C/mιn to 250 °C) m/z[%] = 3!3 (M , 01), 257(27), 240(5), 126(35), 82(59), 80(38), 57(100) Η-NMR (CDCU, 300 MHz) δ = I 43, I 44 [2s, 9H, C(CH,M*, 268 (m, 2H, 3-CH ? ), 357 [t, J - 66 Hz. I H. CH(COOCH,) 2 ], 71, 372 [2s, 6H, CH(COOCH 3 ) ], 397 - 410 (br m, 4H, 2-H.5_ H), 544(br m, IH, 4-H) ppm 13 C-NMR (CDClj, 75 MHz) δ - 280, 281 (2t, 3-CH 2 -)Fehler! Textmarke nicht definiert., 285 [q, C(CH.).], 50 I [d, CH(COOMe) 2 ] 527 (q, OCH.), 531, 533, 545, 549 (4t, C-2. CA)*.794 [s, C(CH.).], 1210(d, C-4), 1358 (s, C-3), 154 I (s, NCOO), 1690 (s, COOMe) ppm h) 3-(2-Methoxycarbonyl-ethyl)-2,5-dihydropyrrole-l -carboxylic acid ten. butyl ester To a solution of 452 g (144 mmol) 2-(\-ten -butoxycarbonyl-2,5-dιhydro-lY- pyrrol-3-yl-methyl)-malonιc acid idimethylester n 140 ml DMF were added 194 g ( 108 mmol) water and 126 g( 216 mmol) sodium chloride The mixture was degassed and heated to 150 °C for 30 h under an atmosphere of argon After this period of time no starting material could be detected by TLC The mixture was cooled to room temperature, diluted with 200 ml ether and washed three times with water, then with brine. The organic layer was dried over MgSO 4 and evaporated. Purification by bulb-to-bulb distillation gave 3.38 g (92 %) of 3-(2-methoxycarbonyl-ethyl)-2,5- dihydropyrrole- 1 -carboxylic acid terl butylester as a colorless oil, b p 1 30 °C (0 2 mbar) GC/MS (HP 5890 II/HP 5972, column HP 5, 30 m x 25 mm x 0 25 μm film thickness, carrier gas helium; temperature gradient 50 °C, 3 min, then with 20 °C/mιn to 250 °C) t« - " - 12 63 mm m/z [%] - 255 (M + , 0 2), 199 (48), 196 (2), 182 ( 10), 126 (26), 82 (54), 80 (32), 57 ( 100) ' H-NMR (CDCI . ., 300 MHz) δ = 13.2, 13.2 [2s, 9H, C(CH . .),]*, 2.30 - 2.35, 2 40 - 2.44 (2m, 2H each, -CH 2 -CH 2 - ), 3 58 (s, 3H, OCH .), 3 91 - 4 00 (m, 4H, 2-H. 5-H), 5 29 - 5 34 (m, I H, 4-H) ppm l C-NMR (CDCI t , 75 MHz) δ = 23 7, 23 8 (t, 3-CH 2 )*, 28 2 [q, C(CH-,),], 3 I 7 (t, CH 2 COOMe), 5 I 4 (q, COOCH 3 ), 52 8, 53. 1 , 54 4, 54 7 (4t, C-2, C-5)*, 78 9 [s, C(CH . .);,J, I 18 9 (d, C-4), I 37 8 (s, C-3 ), 1 53 9 (s, NCOO), ! 72 8 (s, COOCFL) ppm i) 3-|2-(2,2,2- ' ι ' richlorethoxycarbonyl)-amiιιo-ethyl|-2,5-dihydro-pyrroie- l - carboxyiic acid tert. butyl ester To a solution of 3 57 g ( 14 mmol) 3-(2-methoxycarbonyl-ethyl)-2,5-dihydropyrrole- 1 -carboxylic acid tert butyl ester in 45 ml THF/methanol/water 3 I 1 was added I 18 g (28 mmol) LiOH*H 2 O and the mixture was stirred for I h at room temperature The solution was diluted with water and washed three times with ethyl acetate The aqueous layer was cooled in an ice bath and acidified with I N hydrochloric acid against methyi orange The turbid mixture was extracted three times with ether, the combined organic layers were dried over MgSOj and evaporated to yield 3 4 1 g of a colorless soiid. which turned dark on standing The crude acid was dissolved in 140 ml dry toluene and 4.06 g ( 14 mmol) diphenyl phosphoryl azide and 1 47 g ( 14 5 mmol) triethylamine were added The mixture was heated to 80 °C overnight The solvent was removed in vacuo, the residual brown oil was dissolved in 20 ml THF and 3 14 g (21 mmol) 2.2,2-tπchloroethanol and a small amount of cuprous chloride were added The mixture was heated to reflux for 2 h, then the solvent was evaporated and the residue was purified by flash chromatography (petrol ether/ethyl acetate 3 I to 21 ) to yield 431 g (79 %) 3-[2-(2,2,2-trichlorethoxycarbonyl)-amιno-ethyl]-2,5- dihydro-pyrrole-1 -carboxylic acid ten butyl ester as a colorless solid, m p 97-98 °C 'H-NMR (CDC .200 MHz) δ - 141 [s, 9H, C(CH ], 23 I (br m, 2H, 3-CH 2 -), 329 - 339 (m, 2H, CH 2 NH), 467 (br m, 4H, 2-H, 5-H).467 (s, 2H. CH 2 CCI.), 543 (br m, IH, 4-H) ppm 1 C-NMR (CDCL, 50 MHz) δ = 28.6 [q, C(CH 3 ) 3 ], 29.2 (t, -CH 2 -CH 2 -NH), 39.2 (t, -CH 2 -CH 2 -NH), 53.2, 534, 54.6, 549, (4t, C-2, C-5), 745 (d, CH 2 CC1 3 ), 795 [s, C(CH3b], 95.8 (s, CH,CCh), 1208. 1210(2d. C-4), 1363 (s, C-3), 1542, I 546 (2s. NCOO) ppm j) 3-|2-(2,2,2-Trichlorethoxycarbonyl)-amino-ethyl|-2,5-dihydropyrrole-l-(N,N - di-terr.-butoxycarbonyi) carboxamidine To an ice-cooled solution of 1936 g (5 mmol) 3-[2-(2,2,2-trichlorethoxycarbonyl)- amino-ethyl]-2,5-dihydro-pyrrole- 1 -carboxylic acid tert butyl ester in 10 ml dry dioxane was added 10 ml 4N hydrogen chloride in dioxane. The mixture was allowed to stand at 4 °C for 16 h The solvent was then evaporated //; vacuo without heating and then evacuated in high vacuum The residue was suspended in 20 ml dry acetonitrile and 711 mg (55 mmol) ethyldiisopropylamine followed by I 614 mg (52 mmol) N,N -bis-/t?7 -butyloxycarbonyl- 1 H-pyrazole- 1 -carboxamidine were added. The clear solution was stirred for 2 h at room temperature, then the solvent was distilled off and the residue was purified by flash chromatography (petrol ether/ethyl acetate 3 I to 2:1) to yield 2234 g (84 %) of a colorless solid, m p 121 - 123 °C 'H-NMR (CDClj, 200 MHz) δ - I 43 (s, I8H. C(CH, ].227 - 2.33 (br m, 2H, 3-CH 2 -), 328 - 338 (m, 2H. CH,NH), 43 I (br m, 4H, 2-H, 5-H), 4.65 (s, 2H, CH 2 CC ), 547 (br m, IH, 4-H) pm l3 C-N MR (CDCh, 50 MHz) δ = 28 0, 28 1 [2q, 29 0 (t, 3-CH 2 ), 39 0 (t, CH 2 NH 2 ), 55 4, 56 0 (2 br t, C-2, C-5), 74 5 (d, CH 2 CClj), 79 5, 82 0 [2s, C(CH 3 ) 3 ], 95 6 (s, CH 2 CClj), 1 19 9 (d C-4), 1 35 3 (s, C-3), 1 0 4, 1 54 0, 1 54 5, 162 5 (4s, NCOO, N=C-N) ppm k) 3-( 2- A mino-ethy I )-2,5-dihyd ropy rrole- l-(N,N ' -di-tert. -butoxycarbonyl) carboxamidine To a solution of 2 234 g (4 22 mmol) 3-[2-(2,2,2-tπchlorethoxycarbonyl)-amιno- ethyl]-2,5-dihydropyrrole- l -(N,N ' -di-/£'r/ -butoxycarbonyl) carboxamidine in 20 ml glacial acetic acid was added 1 3 1 g (40 g-atom) activated zinc and the mixture was stirred at room temperature for 2 h Methanol was added, the mixture was filtered through celite, washed thoroughly with methanol and the filtrate was concentrated /// vacuo The residue was dissolved in water and made strongly alkaline with solid sodium hydroxide The aqueous layer was extracted three times with ether, the combined organic layers were dried over MgSO 4 and evaporated to yield 622 mg (41 %) 3-(2-amino-ethyl)-2,5-dihydropyrrole- l -(N,N ' -di-tt.r.. -butoxycarbonyl) carboxamidine as a slightly yellow, amorphous solid 'H-NMR (CDC1 , 300 MHz) δ - I 45 [s, 18H, C(CH 3 ) 3 J, 2 2 1 - 2 26, (m, 2H, 3-CH 2 -), 2 83 (t, J = 6 9 Hz, 2H, - CH 2 -NH 2 ), 4 28 - 4 34 (br m, 4H, 2-H, 5-H), 5 46 (br s, I H, 4-H) ppm 13 C-NMR (CDCH, 75 MHz) δ = 27 85, 27 94 [2q, C(CH,) 3 ], 32 2 (t, 3-CH 2 ), 39 5 (t, CH 2 NH 2 ), 55 2, 56 7 (2t, C- 2, C-5), ca 8 1 [br s, C(CH s] . I 19 0 (d, C-4), 136 1 (s, C-3), 1 53 7 (s, NCOO) ppm l) HOOC-CH 2 -D-Cha-(N-cyciopentyl)-Gly-Adc A mixture of 0 4 1 g (0 8 1 mmol) N-(/fc7/. butyloxycarbonyl)-N-(/t77 butyloxycarbonyl- methyl)-(D)-cyclohexylalanyl-N-cyclopentyiglycine, 0 1 5 ml (0 9 mmol) diisopropylmethylamine, and 0 29 g (0 9 mmol) TBTU in 25 ml dry DMF was stirred at room temperature for 30 mm Then 0 3 g (0 85 mmol) (3-(2-amino-ethyl)-2,5- dihydropyrrole-( l -(N,N'-di-/fr/. butoxycarbonyl)-carboxamidine was added and starred for 70 h The solvent was removed 1 vac , water was added and extracted with ethyl acetate The ethyl acetate was separated, washed with I M hydrochloπc acid and 5% aqueous sodium bicarbonate and dried over sodium sulfate Filtration and removal of the solvent 1 vac produced 0 35 g (5 1 %) N-(2- { [ l -(N,N'-dι- ten butoxycarbonyl)-carboxamιdιno]-2,5-dιhydro-pyrrol-3-yl S -ethyl)-[N- (teπ butγloxγcarbonyl)-N-(.tτ. butyloxycarbonyl-methyl)-D-cyclohexylalanvl-(N- cyclopentylglycin)] amide as a colorless oil FAB-MS m/z 847 MH A solution of the above product (0 35 g, 0 41 mmoi) in 10 ml 4 N hydrogen chloride in dioxane was stored for 24 h at 5 °C The solvent was removed i vac, and the oily residue was triturated with diethyl ether to yield the title compound as hydochloπde quantitatively FAB-MS m z 491 MH 'H-NMR (d,,-DMSO, 250 MHz) δ = 0 8 - 4 8 ppm ( in bi oad ) 5 68 ( s I ) N-Me-D-Phe-Pro-Adc The title compound was synthesized as hydrochloride from Boc-N-Me-D-Phe-ProOH (Bajusz et al . J Med Chem 1990, 33, 1729-1735) and 3-(2-amιno-ethyl)-2,5- dihvdropy rrole- 1 -( N N -di-tet i -butoxycarbonyl) carboxamidine (example 3k) by the same method as described in example 31) FAB-MS m/z 4 1 2 MH Example 5: HOOC-CH 2 -D-Cha-Pro-Adc I he title compound was synthesized as hydrochloride from N-((eπ - butvloxycdrbonylmethyl)-N-Boc-D-Cha-ProOH and 3-(2-amιno-ethyl)-2 5-dιhydro- pyrrole- l -(N,N -ώ-ie/ ι -butoxycarbonyl) carboxamidine (example 3k) by the same method as descπbed in example 31) FAB-MS m/z 463 MF1 Example 6: l -{3-|2-( I-amidino-2,5-dihydro- I H-pyrrol-3-yl)-ethyl|-2-oxo-oxazolidin-5- ylmethyl}-pιperidine-4-carboxylic acid (a) A mixture of 3 1 g pιpeπdιne-4-carboxylιc acid ethyl ester 6 4 ml epichlorohydrm and 0 I g tetrabutyl-ammonium bromide in I 5 ml toluene and I 5 ml concentrated sodium hydroxide solution was stirred for 4 h at room temperature and subsequently admixed with 50 ml water The organic phase was separated, the aqueous phase was shaken three times with 20 ml methylene chloride each time, the combined organic phases were dried over sodium sulfate and the solvent was removed in a vacuum 2 1 g (rac)- l-oxιran-2-ylmethylpιpeπdine-4-carboxylιc acid ethyl ester was obtained EI- MS m/z 213 M (b) A solution of 3 g of the amine prepared in example 3k) and 1 73 g of the oxirane produced in 7a) in 20 ml ethanol was heated for 48 h under reflux Subsequently the ethanol was removed in a vacuum and the residue was punfied by column chromatography on silica gel (ethyl acetate/ saturated methanolic ammonia 85/ 15) 1 5 g l -{3-[2-( l -(N,N'-dι-.t.r/ -butoxycarbonyl)carboxamιdιno-2,5-dιhydro- l 7- pyrrol-3-yl)-ethylamιno]-2-hydroxy-propyl }-pιpeπdιne-4-carboxylιc acid ethyl ester was obtained in this way (c) A solution of 0 5 g of the aminoalcohol 7b) and 0 4 g carbonyldnmidazole in 5 mi dimethylformamide was stirred for 24 h at room temperature Subsequently the reaction solution was concentrated to dryness by evaporation and the residue was purified by means of preparative HPLC (Merck, Select B, methanol/buffer (pH=7 5) 65/35) 0 35 g l -{ 3-[2-( l -(N,N'-dι--fcτ7 -butoxycarbonyl)carboxamιdιno-2,5-dιhydro- I H-pyrrol-3-yl)-ethylamιno]-2-hydroxy-propyl }-pιpeπdιne-4-carboxvhc acid ethyl ester was obtamed in this manner (d) A solution of 0 35 g of the ethyl ester 6c) and 2 ml I N sodium hydroxide solution in 5 ml methanol was stirred for I h at room temperature Subsequently the methanol was removed in a vacuum and tthe residue was trearted with 4M Hcl in dioxane for 3 hours at room temperature Then the solvent was removed until drying in vacuo 0 2 g of the title compound was obtained as hydrochlioride FAB-MS m/z366 [MH ] Example 7 Troc-Ada-Gly-Asp-Ser a) 3-(2-Benzhydrilideneamino-2-ethoxycarbonyl-ethyl)-2,5-dihydropyrrole- l - carboxylic acid rt.-butylester To a solution of lithium hexamethyldisilazide, freshly prepared at 0 °C from 1 77g ( I I mmol ) hexainethyldisilazane in 10 ml THF and 4 80 g ( 1 I mmol) n-Butyl-lithium, (2 29 mmol/g in hexanes) and cooled to - 78 °C was dropwise added a solution of 3 06 g ( 1 1 mmol) ethyl N-(diphenylmethylene)-glycinate in 10 ml THF The deep orange enolate solution was stirred at this temperature for 30 m , then a solution of 2 4 1 g ( 10 mmol) 3-acetoxymethyl-2,5-dihydro-pyrrole- 1 -carboxylic acid ten - butylester from example 30 and 426 mg (0 4 mmol) Pd(PPh-,) 4 in 10 ml THF was added dropwise The mixture was allowed to warm to room temperature ov ernight and was then diluted with ether and quenched by addition of sat sodium bicarbonate The aqueous layer was extracted with ether, the combined organic layers were washed with brine, dried over MgSO 4 and evaporated Flash chromatography of the residual oil (elution with petrol ether/ethyl acetate 3 1 + 1 % tπethylamine) gave 3 91 g (8 1 %) 3-(2-benzhydπlidene-amιno-2-ethoxycarbonyl-ethyl)-2,5-dιhydropvrrole- l - carboxylic acid ten. -butylester as a slightly yellow oil ' H-N M R (CDCLJ, 300 MHz) δ = I 27 (t, J = 71 Hz, 3H. OCH . CH,), 143 [s, 9H. C(CH 3 ) . ], 266 - 276 (m, 2H, 3- CH 2 -), 373 - 399 ( m, IH, CH-N), 404 - 409 (br m, 4H, 2-H, 5-H), 417 <q, J - 71 Hz, 2H, OCH 2 CH 3 ), 542 (br m, IH, 4-H) , 711 - 781 (m, 10 H, Ar-H) ppm 13 C-NMR(CDC!3, 75 Mhz) δ = 142 (q, OCH 2 CH,), 285 [q, C(CH 3 ) 3 ], 331 (t, 3-CH 2 ), 529, 551 (2t, C-2, C-5), 61 I (t, OCH 2 CH 3 ), 639 (d, CH-NH 2 ), 791 [s, C(CH-,),], 1219 (d, C-4), 1277, 1281, 1283, 1284, 1285, 1287 (6d, Ar-CH), 1357, 1358 (2s, Ar-C), 1393 (s, C- 3), 154 I (s, NCOO), 1708 (s, N=CPh 2 ), I712 (s, OCOCH 2 CH 3 ) ppm b) 3-( 2- A mino-2-ethoxycarbonyl-eth I )-2,5-dihydropyrrole- l -carboxylic acid tert. -butylester To 25 ml of a 0 5 M solution of methoxylamine hydrochloride in 80 % ethanol was added a solution of 448 mg ( I mmol) 3-(2-benzhydrilideneamino-2-ethoxycarbonyl- ethyl)-2,5-dihydropyrrole- l -carboxylic acid tert. -butylester in 5 ml chloroform After 5 min TLC analysis indicated the complete consumption of the starting material The mixture was stirred for additional 30 min and then evaporated to dryness The residue was dissolved in water and washed twice with ether The aqueous layer was made alkaline by addition of I N potassium hydroxide and extracted three times with ether The combined organic extracts were dried over MgSOα and evaporated to yield 2 14 mg (75%) 3-( 2- amιno-2-ethoxycarbonyl-ethyl)-2, 5-dihydropyrrole- 1 -carboxylic acid ten -butylester as a colorless oil which was pure according to GC GC/MS (HP 5890 II/HP 5972, column. HP 5, 30 m x 25 mm x 0 25 μm film thickness, carrier gas helium, temperature gradient 50 °C, 3 min, then with 20 °C/mιn to 250 °C) t κ - I 3 84 min m/z [%] = 227 (M - C H 9 , < 1 ), 21 1 (7), 182 ( 10), 1 55 ( 1 1 ), 137 (6), 126 (56), 108 ( 18), 94 (23), 82 ( 100), 74 (20), 57 (92) Η-NMR (CDC13, 300 MHz) δ = 123 (t, J = 71 Hz, 3H, OCH . CFL), 142 [s, 9H, C(CH 3 ) 5 ], 235 (dd, 2J -- 142 Hz, ' J - 8 Hz, IH, CH,H b CHNH 2 ), 2.50 - 2.55 (m, IH, CH a H b CHNH ), 354 (dd, J J = 8, 55 Hz, IH, CHNH 2 ), 402 - 411 (br m, 4H, 2-H, 5-H), 413 (q, J = 71 Hz, 2H, OCFbCH 3 ), 5 1 (br m, IH, 4-H) ppm "C-NMR(CDCI3, 75 MHz) δ = 14.1 (q, OCH 2 CH 3 ), 285 [q, C(CH 3 ) 3 ], 345 (t, 3-CH 2 ), 529 (d, CH-NHj).530. 548 (2t, C-2, C-5), 610 (t, OCH 2 CH , 793 [s, C(CHj) 3 ], 1222 (d, C-4), 1355 (s, C-3). 1541 (s, NCOO), 1750 (s, OCOCH 2 CH-.) ppm c) 3-|2-(2,2,2-Trichloroethoxycarbonyl-amiι_o)-2-ethoxycarboιιyl-eth l|-2,5-di- hydro-pyrrole-1-carboxylic acid tert.-butylester To an ice-cooled solution of 214 mg (0.75 mmol) 3-(2-amino-2-ethoxycarbonyl- ethyl)-2,5-dihydropyrrole- l -carboxylic acid ten. -butylester and 1 19 mg ( 1 5 mmol ) pyridme in 2 ml methylene chloride was added a small amount of DMAP followed by 2 12 mg ( I mmol) 2.2,2-trichloroethoxycarbonyl chloride The mixture was allowed to warm to room temperature overnight The mixture was diluted with ether, washed with water, sat CuS0 , water and brine, dried over MgSO and evaporated Purification of the residue by flash-chromatography (elution with petrol ether/ethyl acetate 3. 1 ) gave 320 mg (93 %) 3-[2-(2,2,2-trichloroethoxycarbonyl-amino)-2- ethoxycarbonyl-ethyl]-2,5-dihydropyrrole- l -carboxylic acid ten -butylester as a colorless oil, which was immediately used for the next step d) 3-|2-(2,2,2-Trichloroethoxycarbonyl-amino)-2-ethoxycarbonyl-eth l|-2,5-di- hydropyrrole- l -(N,N'-di-t<?rt.-butoxycarbonyl) carboxamidine To an ice-cooled solution of 320 mg (0 67 mmol) 3-[2-(2,2,2- trichloroethoxycarbonyl-amino)-2-ethoxycarbonyl-ethyl]-2,5-dihydropyrrole- l - carboxylic acid te . -butylester in 1 .5 ml dry dioxane was added I 5 ml 4 N hydrogen chloride in dioxane. The mixture was allowed to stand at 4 °C for 16 h The solvent was then evaporated in vacuo without heating. The residue was suspended in 4 ml dry acetonitrile and 2 I 7 mg (0 7 mmol) ethyldiisopropylamine followed by 97 mg (0 75 mmol ) N N " -bιs-/< r. -butvloxvcarbonyl- 1 H-pyrazole- 1 -carboxamidine were added T he resulting clear solution was stirred for 2 h at room temperature, then the solvent was distilled off and the residue was purified by flash chromatography (petrol ether/ethyl acetate 3 1 to 2. 1 ) to yield 380 mg (94 %) of a colorless foam 'H-NMR (CDC13, 200 MHz) δ= I 2 1 (t. J = 7 0 Hz. 3H. OCH1CH3). I 43 [s. 9H. C(CH ι J. 2 53 - 2 64 ( m 211 OU ' HNH ), 4 16 (q, J - 7 0 Hz. 2H. OCHjCHj). 4 29 (br , 4H. 2-H. 5-H ), 4 67 s, 21 1, CH .CCI . ), 5 52 - 5 6 1 (111. 3 H, -CHNH.4-H) ppm l3 C-N M R (CDC13, 50 MHz) δ - 14 I (q, OCH 2 CHO, 280.282 [2q, C(CH,),], 318 (t, 3-CH t ).529 (d, CH- NH 2 ), 554, 571 (2br t, C-2. C-5), 619 (t, OCH.CHj), 747 (t, CH . .CCU), 95, 835 [2s, C(CH 3 )i], 953 (s, CH 2 CC ), 1 19 (d, C-4), 1333 (s, C-3).1540(s. NCOO), 3B 171 1 (s, COOEt) ppm (BOC-NCOO- and amidine -N-C = N-sιgnals not v isible due to line broadening) e) 3-|2-(2,2,2-Trichloroethoxycarbonyl-amino)-2-carboxy-ethyl|-2,5-dihydro pyrrole- l-(N,N'-di- rt.-butoxycarbonyl) carboxamidine To a solution of 2 19 mg (0 36 mmol) 3-[2-(2,2,2-tπchloroethoxycarbonyl-amιno)-2- ethυxycarbonyl-ethyl]-2,5-dιhydropyrrole- 1 -(N,N'-dι-/t./7 -butoxycarbonyl) carbox¬ amidine in 4 ml THF/methanol/water3 1 1 was added 30 mg (0 72 mmol) LιOH*H2O After stirring for l h at room temperature no starting material could be detected by TLC The mixture was diluted with water, acidified by addition of 1 N hydrogen chloride and extracted three times with ethyl acetate The combined organic extracts were dried over MgSO 4 and evaporated The residue was purified by flash- chromatography (elution with ether + 1% acetic acid) to vield 1 56 mg (76 %) 3-[2- (2,2,2-trιchloroethoxycarbonyl-amιno)-2-carboxy-ethyl]-2,5-dιhydropyrro!e- l -( N N'- ώ-tei t -butoxycarbonyl) carboxamidine (Troc-Ada(Boo)-OH) as a colorless amorphous solid ' H-NMR (CDC13, 250 MHz) δ - 1 42 [s I 8H, C(CH,) 3 ], 2 58 - 2 79 (br m. 2H, CH 2 CHNH), 4 30 - 4 38 ( m 4H 2-H, 5-H), 4 58 (d, J - 12 2 Hz, I H, CH a Ht,CCI 3 ), 4 75 (d, J - 12 2 Hz I H. CH jhCC ), 5 53 (br s I H, CHNH), 5 99 (bi m, I H 4-H) ppm f) T roc-Ada-Gly-Asp-Ser I he title compound was synthesized by solid-phase methodology on a SyRo 11 multiple peptide synthesizer (MultiSynTech, Bochum) on a 0 03 mmol scale using Fmoc-Ser(t-Bu)-tπtyl-polystyrene( 1 %)dιvιnylbenzene resin (Fmoc-L-Ser(t-Bu)-TCP, loading 0 57 mmol/g, PepChem Tubingen) as starting material The α-amino groups of the protemogenic amino acids Gly and Asp were protected by 9- fluorenylmethoxycarbonvl (Fmoc), the side chain carboxy group of Asp b\ ten -buty l The non-proteinogenic amino acid Ada was used as Troc-Ada(Boc )-OH (from example 8e) The Fmoc-protected ammo acids were coupled in a 6-told excess tor 30 min in DMF TBTU ( 1 eq) and NNM ( 1 eq) were used as activating reagents Cleavage of the Fmoc group was carried out in pipeπdine/dimethvlformamtde ( 1 1 v/v ) tor 2 x 10 min oupling of Troc-Ada(Boc >)-OH was performed manually in DMF within I h by using 0 048 mmol of the protected amino acid ( I 65-fold excess) and equi olare amounts of TBTU and NMM for activation ' I he peptide was cleaved from the resm with 750 ul of acetic acid/tπfluoroethanol/dichloromethane ( 30 10 70) within 2 h After washing five times with 1 50 ul of the same solvent mixture the filtrates were combined, diluted with 10 ml heptane and concentrated This procedure was repeated twice in order to remove the acetic acid completely The oily residue was dissolved in 5 ml 4 N hydrogen chloride in dioxane To this solution 270 ul ethanedithiol were added and the mixture was stirred for 3 h at room temperature Then the solvent was removed and the residue dissolved in heptane and concentrated again several times until the ethanedithiol was almost completely removed The crude peptide as lyophili/ed from ten -butanol/watei ( 1 1 ) and yielded 1 ^ m f Ti oc- Λda-Glv- Λsp-Ser • HCl as white lyophilisate Amino acid analysis: Gly 1 09( 1 ), Asp 1 00( 1 ), Ser 0 95( 1 ), peptide content 69 9 % ESI-MS: m/z 63 1 I M + Example 8: I roc-Ada-Gly-Asp-Trp The title peptide was prepared in the same manner as example 70 starting from 50 mg (0 03 mmol) Fmoc-I -Trp-TCP resin 16 mg of Troc-Ada-Glv-Asp-Trp • HCl were obtained as white lyophilisate Amino acid analysis: Gly 1 1 9 ( 1 ), Asp 0 88 ( I ), Trp 1 00 ( 1 ), peptide content 61 2 % ESI-MS: m. / 730 2 M 4 Example 9: Troc-Ada-Gly-Asp-Phe The title peptide was prepared in the same manner as example 70 starting from 50 mg (0 03 mmol) Fmoc-L-Phe- TCP resin 14 mg of Troc-Ada-Gly-Asp-Phe • HCl were obtained as white lyophilisate Amirio acid analysis: Glv I 08 ( 1 ). Asp I 00 ( 1 ), Phe 0 93 ( 1 ), peptide content 65 0 % pos. LSIMS: m z 692 1 MH + The Troc protecting group of the compounds of example 7 to 9 can be removed by standard chemical reactions Example 10: Ada-Gly-Asp-Tyr a) 3-Acetoxymethyl-2,5-dihydro-pyrrole-l-(N,N ' -di-tert. -butoxycarbonyl) carboxamidine To an ice-cooled solution of 1 21 g (5 mmol) 3-acetoxymethyl-2,5-dihydro-pyrrole- l - carboxv lic acid ten -butylestei from example f) in 10 ml di v dioxane was added 10 ml 4N hydrogen chloride in dioxane The mixture was stirred at 0 °C for 16 h The mixture was evaporated to dryness without heating and then evacuated in high vacuum for several hours The dark residue was suspended in 20 ml dry acetonitrile and 776 mg (6 mmol) ethyl diisopropylamine, followed by I 71 g (5 5 mmol ) N,N - bιs-/tτ. -butyioxycarbonyl- 1 /7-pyrazole- 1 -carboxamidine were added The mixture was stirred for 2 h at room temperature and then evaporated and purified by flash chromatography ( petrol ether/ethyl acetate 3 I to 2 1 ) to yield I 87 g (97 %) of 3- aceto vmethyl-2,5-dihydro-pyrrole- l -(N, N"-dι-/t'/7 -butoxycarbonyl ) carboxamidine as a colorless, sticky solid ' H-NMR (CDC 300 MHz) δ = I 45 (s, I 8H, 2 t-Bu), 2 03 (s, 3H, OAc), 4 38 (br m, 4H, 2-H, 5-H), 4 61 (s, 2H. CH OAc), 5 72 (br m, I H, 4-H), 10 22 (br s, I H, NH) ppm ,3 C-N M R (CDCIi, 7S MHz) o - 20 4 (q, OOCCH j ). 27 7, 27 9 [2q, C(CH,) 3 |, 55 ϋ ( br 1. C-2, C- 5 ) o0 2 ( [. C LOAc). 79 3, 8 1 8 [2 br s, C(CH 3 ) ], 122 4 (d, C-4), 1 33 5 (s. C- 3 ). I SO ( br s. NCOO), 153 9 (s, NC=N), 162 (br s, NCOO), 170.2 (s, OOCH 2 CH 3 ) ppm b) 3-(2-Benzhydrilideneamino-2-ethoxycarbonyl-ethyl)-2,5-dihydropyrrole- l - (N,N ' -di- rt. -butoxycarbonyl) carboxamidine l o a solution of lithium hexamethyldisilazide, freshly prepared at 0 °C from 7 10 mg (4 4 mmol ) hexamethyldisiiazane in 8 ml THF and I 92 g (4 4 mmol ) n-Butvl-lithium (2 29 mmol/g in hexanes) and cooled to - 78 °C was added a solution of I 069 g (4 mmol) ethvl N-(diphenvlmethviene)-glycmate in 8 ml THF The orange enolate solution was stirred for 30 min at -78 °C, then a solution of 1 039 g (3 7 mmol) 3- acetoxymethyl-2,5-dιhydro-pyrroie- l -(N,N -butoxycarbonyl) carboxamidine and 426 mg (0 4 mmol ) Pd(PPh.) in 12 ml THF was added dropwise The reaction mixture was allowed to warm to room temperature over 2 h and was stirred for additional 12 h The mixture was diluted with ether and quenched by addition of sat NaHCO. Ihe organic layer was washed with sat NaHCO. and brine, dried over MgS() 4 and evaporated Purification by flash chromatography (ethyl acetate/petrol ether I 5 T 1% tπethylamine) gave I 03 g (47 %) of 3-(2-benzhydrylideneamino-2- ethoxycarbonyl-ethyl)-2,5-dihydropyrrole- 1 -(N,N ' -di-/fc77. -butoxycarbonyl) carboxamidine as a colorless, amorphous solid 1 H-NMR (CDC1 3 , 300 MHz) 6= 12.3 {[../-- 1 I Hz, 3H. OCH 2 CH 3 ), 146 [br s. I 8H, C(CH.).], 268 (br m, 2H, 3-C1L-), 396 (br m, IH, CH-N), 4 I 5 (q, ./ - 71 Hz, 2H, OCH 2 CH*), 416-429 (br m, 411, 2-H, 5-H).5 1 (br m, IH.4-H), 707 - 7(.ϋ(m, 10 H. Ar-H) ppm δ= 139(q, OCH 2 CH 3 ), 280 [q, C(CH 3 ) 3 ], 325 (t, 3-CH 2 ), 552, 569 (2t. C-2, C-5), 609 (t, OCH 2 CH ), 636 (d, CH-NH 2 ), 79, 816 [2 br s, C(CHj),], 1207 (d, C-4), 1275, 1278.1284, 1285, 1286, 130.2 (6d. Ar-CH), I 348 (s, C-3), 1358, 139 I (2s. Ar-C).1 SO (br s. NCOO), 1537 (s, NC=N).162 (br s. NCOO). 1707 (s. c) 3-(2-Amiι.o-2-ethoxycarboιιyl-ethyl)-2,5-dihydropyrrole-l-(N,N ' -di-t..rt.- butoxycarbonyl) carboxamidine To a solution of 118 mg (0.2 mmol) 3-(2-benzhydrilideneamino-2-ethoxycarbonyl- ethyl)-2,5-dihydropyrrole-l-(N.N -di-/er.. -butoxycarbonyl) carboxamidine in 2 ml THF was added I ml IN hydrochloric acid The mixture was stirred at room temperature for 30 min Water (5 ml) was added, the aqueous layer was separated and washed twice with ether. The aqueous layer was brought to pH = ■ - 85 by addition of IN NaHCO and was extracted five times with ether The combined ether layers were washed with brine, dried over MgSO and evaporated The residue was purified by flash chromatography (chloroform/methanol 20 I ) to yield 79 g (93 %) 3-(2-amino- 2-ethoxycarbonyl-ethyl)-2,5-dihydropyrrole- 1 -(N,N -di-/t'/7. -butoxycarbonyl) carbox¬ amidine as a colorless oil Η- MR (CDClj, 300 MHz) 6 -- I 22 (t, J - 71 Hz, 3H, OCH 2 CHj), 145 [s, 18H, C(CH. ( )iJ. ~ 3 (dd, A - 160 Hz, 81 Hz, IH, CH,H,.CHNH : ), 254 (dd, A 166 Hz, A ■ S 3 Hz, 111, CHaH„CHNH 2 ), 354 (dd, l = 81, 5.3 Hz, IH, CH a H b CHNH>).41 (q, .1 -- 71 Hz, 2H, OCHjCHi), 433 (br m, 4H, 2-H, 5-H), 553 (br m, IH.4-H) ppm l C-NMR(CDCI 3 , 75 MHz) o - 139(q, OCH 2 CH,), 279 [q, C(CH.) 3 ], 34 I (t.3-CH 2 ).527 (d. CHNH,).553, 569 (2d . C-2. C-5), 61. I (t, OCH 2 CH 3 ). ca 80 [2 br s, C(OI 3 ) 3 ]. 1207 (d. C-4). 1346 (s, C-3), 1538 (s, NC-N), 1746 (s, OOCH 2 CH 3 ) ppm d) 3-(2- rt.-Butoxycarbonyl-amino-2-ethoxycarbonyl-ethyl)-2,5-dihydropyrrole- l-(N,N ' -di-tέ?rt. -butoxycarbonyl) carboxamidine To a solution of 79 mg (019 mmol) 3-(2-amino-2-ethoxycarbonvl-ethyl)-2.5- dihydropyrrole- 1 -(N,N -di-/c/7. -butoxycarbonyl) carboxamidine in I ml dry acetonitrile was added 40 mg (03 mmol) ethyl diisopropylamine and 65 mg (0.3 mmol) di-tert -butyl dicarbonate (Boc 2 O) and the mixture was stirred for 16 h at room temperature The solvent was evaporated and the residue was purified by flash chromatography (petrol ether/ethyl acetate 21 ) to yield 8.3 mg ( 76 %) 3-(2-terr - butoxycarbonyl-amino-2-ethoxycarbonvl-ethvl)-2,5-dihydropvrrole- l-(NN -di-ierr - butoxycarbonyl) carboxamidine as a colorless oil 'H-NMR (CDCI 3 .200 MHz) δ - ■ 122 (t, ./ --- ■ 7 I Hz, 3H. OCHCH 3 ), I 42, I 47, 148 [3 s, 9H each, C(CH 3 ),], 2.41 - 266 (br m, 2H, 3-CH 2 -), 4 l7(q,J- 71 Hz, 2H, OCHCH , 32 (br , 4H, 2-H, 5-H), 502 (br m. IH, CHNH), 552 (br s. IH.4-H) ppm 13 C-NMR (CDCU, 50 MHz) δ - 14 I (q, OCH 2 CH 3 ), 28 I.283, 285 [3q, C(CH 3 ) 3 ], 3 I 8 (t.3-CH ? ), 483 (d. CHNH), 520, 553 (2t, C-2, C-5), 616 (t, OCfLCHj), 1213 (d, C-4), 1335 (s, C- 3), 1539(s, N=C-N), I 7 I 8 (s, COOEt) ppm NCOO-. C(CHj) 3 -signals not visible due to line broadening e) 3-(2-tt'rt.-Butoxycarbonyl-amino-2-carboxy-ethyl)-2,5-dihydropy rrole- 1 - (N,N -di-tert. -butoxycarbonyl) carboxamidine To a solution of 267 mg (0 63 mmol) 3-(2-tert -butoxycarbonyl-amιno-2-ethoxy- carbonyl-ethyl)-2,5-dιhydropyrrole- l -(N,N -d\-terι. -butoxycarbonyl) carboxamidine in 5 ml THF/methanol/water 3 I I was added 50 mg (1 2 mmol) LiOH*H 2 O After 30 min stirring at room temperature no starting material could be detected by TLC The mixture was made acidic by addition of I N HCl, diluted with water and extracted three times with ether The combined organic extracts were washed with brine, dried over MgSO and evaporated The residue was purified by tlash-chromatography to give 98 mg (3 I %) of 3-(2-.</τ. -Butoxvcarbonyl-amino-2-carboxv-ethyl)-2.5- dιhydropyrrole- l -( N,N -dι-/c/7. -butoxycarbonyl) carboxamidine (Boc-Ada(Boc. )-OH) as a colorless amorphous solid Η-N M R (CDC13, 300 MHz) δ = I 39, 1 44 [2s, 9H, 18H, C(CH_) 3 ], 2 49 - 2 67 (br m. 2H, 3-CH <-),4 33 (br m, 4H, 2-H, 5-H), 5 30 (br d, 1 H, CHNH), 5 56 (br s, 1 H, 4-H) ppm 13 C-N M R (CDC13, 75 MHz) δ = 277, 289.280 [3q, C(CH .], 313 (t, 3-CH 2 ), 520 (d, CHNH), 553, 569 (2t, C-2, C-5).800, 809[2s, (C(CH,)j], 121 1 (d, C-4), 1336 (s, C-3), 1532(s, N=C- N), 1552 (br s, NCOO), I765 (s, COOH) ppm f) Ada-Gly-Asp-Tyr The title peptide was prepared in same manner as example 80 starting from 50 mg (0 03 mmol) Fmoc-L-Tyr-TCP resin instead of Troc-Ada(Boc_)-OH Boc- Ada(Boc 2 )-OH from example 12e) was used for the N-terminal amino acid I 2 mg of Ada-Gly-Asp-Tvi • HCl were obtained as white lyophilisate Amino acid analysis: Gly 1 05 ( 1 ), Asp 0 96 ( 1 ), Tyr I 00 ( I ), peptide content 61 1 % pos. LSIMS: m/z 534 3 MH + Example 1 1 Ada-Gly-Asp-Phe-N H 2 The ntle compound was sy nthesized by solid-phase methodology on a ACT90 automated peptide svnthesizer (Advanced ChemTec, Louisville, Kentucky) using ιrιιylchloπde-polystyrene( l %)dιvιnylbenzene (TCP, loading 0 96 mmol/g, PepChem, Tubingen) and Fmoc-Asp-Phe-NH2 (NovaBiochem, Laufelfingen) as starting materials The Fmoc-protected dipeptide amide (320 4 mg, 0 72 mmol) was dissolved in 4 ml dichloromethane After I eq N-methyl-morpholin ( NMM ) was added the solution was given to 444 mg (0 48 mmol) dry TCP resin After 5 m an additional v olume of 1 30 ul NMM was added yielding a total amount of I 80 mmol NMM in solut ion The mixtui e was shaken for further 60 mm Then the l esidual intylchloride groups were capped by the addition of 0 5 ml methanol After further 20 mm the resin was filtered off and washed with dichloromethane, DMF and methanol The resin was dried under reduced pressure Loading of the resin was determined to be 0 057 mmol/g The Fmoc group was removed by treatment with piperidine/dimethylformamide ( I I v/v) for 2 x 10 min Afterwards Fmoc-Glv-OH was coupled within 30 min in 30-fold excess in a double coupling procedure using 1 eq I B Tl ' and I eq NMM as activing agents After removal of " the Fmoc group by the same procedure as described above Boc-Ada(Boc . )-OH was coupied manually in DMF within I 7 h by using a 2 5-fold excess of the protected amino acid and equimolar amounts of TBTU and NMM for activation Cleavage from the resm and deprotection of the peptide was performed according to example 8f) Instead of heptane tntluoroethanol (2 ml ) was used to dissolve the deprotected peptide From this solution the crude peptide was precipitated bv the addition of 16 ml diethylether After centrifugation the supernatant was discarded and the precipitate Ivophilized from ten -butanol/water ( I I v/v) Ada-Gly-Asp-Phe-NH2 • HCl (28 mg) was obtained as white lyophilisate Amino acid analysis: Gly 1 05 ( 1 ), Asp I 03 ( I ), Phe 0 97 ( I ), peptide content 67 4% pos. LSI MS: m/z 502 3 MW r.xample 1 2 Description of the pharmacological experiments Thrombin time A common test in clinical coagulation diagnostics is the thrombin time This parameter detects the action of thrombin on fibrinogen and the formation of blood clots Inhibitors of thrombin result in an increased thrombin time in ordei to obtain plasma 9 parts fresh blood from healthy donors are mixed with one part sodium citrate solution (0 1 1 mol/1) and centrifuged at ca 3000 rpm for 1 0 mm at l oom temperature The plasma was removed by pipette and can be stored foi ca 8 h at room temperature 200 μl citrate plasma was incubated for 2 mm at 37°C in a sphere coagulometei (KC 10 from the Amelung Company) 10 μl dimethylsulfoxide (DMSO) or a solution of the active substance in DMSO was added to 190 μl preheated thrombin reagent (Boehπnger Mannheim, GmbH, contains ca 3 U/ml horse thrombin and 0 01 25 M Ca2+ ) A stopwatch was started when this 200 μl solution was added to the plasma and the time point at which coagulation starts was determined In the control measurements the thrombin time was ca 24 seconds and was increased by the compound of example 3 depending on the concentration (test concentration/ inα ease of thrombin time 5 μ M '■> 300* sec 0 5 μM ' 96 sec. 0 05 μ ^ sec ) [ * t he experiment was stopped after 5 minutes ] Thrombin inhibition The kinetic measurements were carried out in 0 1 M phosphate buffer which contained 0 2 M sodium chloride and 0 5 % polyethylene glycol 6000 at a pH = 7 5 and 25°C using the substrate H-(D)-Phe-Pro-Arg-pN A ( S-2238 Kabu and human thrombin ( Sigma, specific activity = 2 1 50 NIH-units/mg) in polyslyi ene semimiα υ- cuvettes in a total volume of I ml In a preexpeπment is was determined whether the compound of formula ( I ) inhibits thrombin rapidly or slowly For this the reaction was started first by adding 0 03 N IH units thrombin to a 100 μM solution of the substrate and the active substance In a second experiment substrate was added to a solution of thrombin and the active substance w hich had been incubated foi 5 mm The mci ease of ' the concenti ation ot p- nitro-anilide with time was monitored spectrophotomeiπcally for 12 min at 405 nm (UV-VIS spectrophotometer Lambda-2 from the Perkin-Elmer Company) Since the measurement curves obtained in both experiments were lineai and parallel the active substance of formula (I) is a rapid tho bin inhibitor The inhibition constant Ki was determined as follows The substrate was added at concentrations of 100 μM 50 μM 30 μM, 20 μM and at each substrate concentration a measuiement was carried out without inhibitor and three measurements were earned out in the presence of various concentrations of the inhibitor of formula (I) The reactions were started by addition of thrombin The increase in absorbance at 405 nm caused bv the formation of p nitroanilide was monitored for a time period of 12 mm Measurement points (time versus absoi bance) were transfeπ ed to a PC at intervals of 20 sec I he l ates v o ( changes in absorbance per sec measurements w ithout inhibitor) and V i ( measui ements with inhibitor ) wei e determined f rom the data bv lineai l egi ession Only that part of each measurement was used in which the substrate concentration had been reduced by less than 1 5 % From one measurement series (constant inhibitor concentration, variable substrate concentrations) Km' and Vmax were determined by a non-linear fit to the equation V max * [S] V = [S] + Km Finally Ki was determined from the total series of measurements by non-linear fit to the equation V max * [S] V - - The Michaelis constant Km was 3 8 + 2 μM in all measurements The compound of example 4 inhibits thrombin Inhibition of trypsin 10 mg bovine pancreatic trypsin (Sigma) was dissolved in 100 l M hydrochlonc acid and stored in a refrmeraior 20 μl thereof was admixed with 980 μl I mM hydrochloric acid. 25 μl thereof was used for each measurement The measurement was carried out as described for thrombin Km - 45 μM The compound of example 1 inhibits trypsin with an inhibition constant Ki of 100 nM 5 GpIIb/IIla inhibition The Gpllb/llla fibrinogen Elisa is a modification of assays which are descnbed in the following literature Nachman, R L. & Leung, L.L.K. ( 1982) J Clin Invest 69 263- 269 and Wright, P S et al ( 1993) Biochem J 293 263-267 l ϋ Microtitre plates were coated overnight with 2 μg/ml isolated activated pl lb/I 1 la receptor After unbound receptor had been removed by washing several times the surface of the plates is blocked with 1 % casein and it is washed again The test substance is added at the required concentrations and the plates are incubated for 10 15 minutes while shaking. The natural ligand of the gpllb llla receptor, fibrinogen, is added After incubating for 1 hour unbound fibrinogen is removed by washing several times and the bound fibrinogen is determined by means of a peroxidase-conjugated, anti-fibrinogen monoclonal antibody by measuring the optical density at 405 nm in an ELISA instrument The inhibition of a fibrinogen-GpIIb/lIIa interaction results in a 0 low optical density. The IC50 value was determined by a concentration/effect curve 5

Claims: Claims Compounds of formula 1 in which R 1 , R2 and Y can be the same or different and denote hydrogen or an organic residue and their optically active isomers as well as pharmacologically acceptable salts or prodrugs thereof 2 Compounds of formula I as claimed in claim I in which Rl , R2 can be the same or different and denote hydrogen, an amino acid peptidyl, alkylsulfonyl or arylsulfonyl residue, Y denotes hydrogen or a residue of formula COX, X denotes hydrogen, an OR3 or NR TR2' residue R3 denotes hydrogen or lower alkyl such as methyl, ethyl, piopyl or butvi and R l ' R2' can be same or different and have the meanings oi the residues R l and R2 and their optically active isomers as well as pharmacologically acceptable salts oi prodrugs thereof 3 Pharmacological composition containing at least one compound of the general formula I as claimed in one of the claims I or 2 in addition to the conventional carrier and agents 4 Use of compounds of formula 1 as claimed in one of the claims I or 2 for the production of a pharmaceutical composition for treatment of diseases which are due to thromboembolic events, osteoporosis, inflammations or tumour diseases Use of the structure 1 n arginine mimetic in a compound comprising a arginine structure or a known mimetic of said arginine structure wherein Y denotes for H or COR3 and R l , R2, R3 denote for different residues of an arginine or a known arginine mimetic structure of said compound

Inventors: ENGH RICHARD, KONETSCHNY-RAPP SILVIA, KRELL HANS-WILLI, MARTIN ULRICH, TSAKLAKIDIS CHRISTOS, ENGH, RICHARD, KONETSCHNY-RAPP, SILVIA, KRELL, HANS-WILLI, MARTIN, ULRICH, TSAKLAKIDIS, CHRISTOS
Applicants: BOEHRINGER MANNHEIM GMBH, ENGH RICHARD, KONETSCHNY RAPP SILVIA, KRELL HANS WILLI, MARTIN ULRICH, TSAKLAKIDIS CHRISTOS, ENGH, RICHARD, KONETSCHNY-RAPP, SILVIA, KRELL, HANS-WILLI, MARTIN, ULRICH, TSAKLAKIDIS, CHRISTOS
Application year: 1996
Main classification: C07K5
IPC codes: A61K31, A61P7, A61P9, A61P19, A61P29, A61P35, A61P43, C07D207, C07D413, C07K5, C07K14